Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Device Design & Manufacturing
quidel.com

See what CB Insights has to offer

Partners & Customers

10

Service Providers

2

About Quidel

Quidel (NASDAQ: QDEL) develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.

Quidel Headquarter Location

12544 High Bluff Drive 200

San Diego, California, 92130,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Quidel Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Quidel Rank

Latest Quidel News

07:15 EDT Influenza Diagnostic Tests Market worth USD 3.5 Billion by 2028, Says Global Market Insights Inc.

May 17, 2022

. News provided by Share this article Share this article Some of the major market players operating in the influenza diagnostic tests industry include Quidel Corporation, Abbott, DiaSorin SpA, Thermo Fischer Scientific Inc., Becton, Dickinson and Company, Meridian Bioscience Inc., and F. Hoffmann-La Roche Ltd.  SELBYVILLE, Del., May 17, 2022 /PRNewswire/ -- The influenza diagnostic tests market value is projected to reach USD 3.5 billion by 2028, according to a new research report by Global Market Insights Inc. Recent developments in influenza diagnostic tests along with rise in demand for rapid diagnostic tests are anticipated to augment the industry size. Influenza Diagnostic Tests Market Recent technological developments and the incorporation of novel modalities in the field of influenza diagnostic tests will accelerate the market forecasts. In the past years, major developments in influenza diagnostic tests technologies have incorporated advanced signal enhancement approaches, increased application of new labels, enhanced quantification techniques, and continuous detection. Such developments have enabled the use of influenza tests in applications that mandate high precision and sensitivity; while maintaining the clinical benefits such as low infrastructure requirements, cost-effectivity, and user-friendliness. This has enabled for enhanced range of applications in fields such as decentralized testing environments, clinical diagnostics, and others. Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/4242 Influenza diagnostic tests Market from traditional diagnostic tests segment was valued at USD 1,359 million in 2021. Ongoing technological advancements in traditional diagnostic tests such as rapid influenza diagnostic tests, viral culture, and serological assay leading to the introduction of advanced tests are set to drive business landscape. These diagnostic tests deliver a precise interpretation of outcomes for research & development activities and sample testing. The emergence of digital rapid influenza diagnostic tests with the rising use of digital connectivity is further set to promote the capabilities of these testing products. One of the recent advancements in these testing involves the use of progressive computer technologies including artificial intelligence (AI). This would improve the quality of the diagnosis, provide precision, and predict disease progression. Some major findings of the influenza diagnostic tests market report include: The ability of technologically advanced influenza diagnostic tests to reduce the timelines of sample processing has led to the high adoption rate amongst diagnostic centers and hospitals that are likely to drive the business revenue. Rise in prevalence of influenza coupled with the implementation of potential strategies for increasing this infectious disease diagnosis across the globe will propel the market expansion. Competitors are emphasizing strategic collaborations, partnerships, and product launches to garner significant market share and improve their market position. Browse key industry insights spread across 120 pages with 233 market data tables & 14 figures & charts from the report, "Influenza Diagnostic Tests Market Analysis By Test Type (Traditional Diagnostic Test {Rapid Influenza Diagnostic Test (RIDT), Direct Fluorescent Antibody Test (DFAT), Viral Culture, Serological Assay}, Molecular Diagnostic Assay {RT-PCR, Loop-mediated Isothermal Amplification-based Assay (LAMP), Nucleic Acid Sequence-based Amplification Test (NASBAT), Simple Amplification-based Assay (SAMBA)}), End-use (Hospitals, Diagnostics Centers, Research Laboratories), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028" in detail along with the table of contents: Influenza diagnostic tests market from research laboratories segment is estimated to cross USD 757 million by 2028. A growing number of research laboratories that are delivering advanced diagnostic services will lead to a high preference for these facilities. The augmented adoption and launch of high-quality influenza diagnostic testing products for use in research laboratories is also driving the segment revenue. Diagnostic tests available for influenza in research laboratories comprise viral culture, serological assay, rapid antigen testing, and reverse transcription polymerase chain reaction among others. The standardized conditions maintained by research laboratories perform a crucial role in the sensitivity & specificity of influenza diagnostic tests. China influenza diagnostic tests market is poised to surpass USD 267 million by 2028. The growing prevalence of flu and the rapidly aging population in China is stimulating the demand for influenza diagnostic tests. Poor sanitary conditions in a rural region in China are further expected to spur the adoption of these tests. Also, several industry players in the country have recently introduced sequencing and analysis instruments in order to tackle the surging intricacy of this disease diagnosis. Numerous companies are emphasizing on the integration of technologies including digital PCR (dPCR) for DNA detection and quantitative real-time polymerase chain reaction. Owing to these innovations, influenza diagnostic tests are extensively adopted to screen the eradication effectiveness in China. Some of the major market players operating in the influenza diagnostic tests industry Quidel Corporation, Abbott, DiaSorin SpA, Thermo Fischer Scientific Inc., Becton, Dickinson and Company, Meridian Bioscience Inc., and F. Hoffmann-La Roche Ltd. Request for customization of this research report @ https://www.gminsights.com/roc/4242 About Global Market Insights Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology. Contact Us:

Quidel Acquisitions

6 Acquisitions

Quidel acquired 6 companies. Their latest acquisition was Ortho Clinical Diagnostics on December 23, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/23/2021

$99M

Acq - Pending

2

7/17/2017

Subscribe to see more

$99M

Subscribe to see more

10

5/17/2017

Subscribe to see more

$99M

Subscribe to see more

10

5/7/2013

Subscribe to see more

$99M

Subscribe to see more

10

2/16/2010

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

0

Date

12/23/2021

7/17/2017

5/17/2017

5/7/2013

2/16/2010

Investment Stage

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Acq - Pending

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

0

Quidel Partners & Customers

10 Partners and customers

Quidel has 10 strategic partners and customers. Quidel recently partnered with chicago blackhawks on December 12, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

12/15/2021

Partner

Quidel Announces Sponsorship and Community Partnership With the Chicago Blackhawks

In the first year of the partnership agreement , the Blackhawks will work with Quidel Corporation to provide QuickVue At-Home OTC COVID-19 Test 's free-of-charge to multiple Chicago Blackhawks Foundation community partners to help support local youth and their program staff to continue to learn and play with greater peace of mind .

1

12/15/2021

Partner

Quidel Announces Sponsorship and Community Partnership With the Chicago Blackhawks

In the first year of the partnership agreement , the Blackhawks will work with Quidel Corporation to provide QuickVue At-Home OTC COVID-19 Test 's free-of-charge to multiple Chicago Blackhawks Foundation community partners to help support local youth and their program staff to continue to learn and play with greater peace of mind .

1

12/15/2021

Sponsored

Quidel Corporation - Quidel Announces Sponsorship and Community Partnership With the Chicago Blackhawks

In the first year of the partnership agreement , the Blackhawks will work with Quidel Corporation to provide QuickVue At-Home OTC COVID-19 Test 's free-of-charge to multiple Chicago Blackhawks community partners to help support local youth and their program staff to continue to learn and play with greater peace of mind .

1

10/28/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

5/17/2021

Distributor

United States

Subscribe to see more

Subscribe to see more

10

Date

12/15/2021

12/15/2021

12/15/2021

10/28/2021

5/17/2021

Type

Partner

Partner

Sponsored

Partner

Distributor

Business Partner

Country

United States

United States

News Snippet

Quidel Announces Sponsorship and Community Partnership With the Chicago Blackhawks

In the first year of the partnership agreement , the Blackhawks will work with Quidel Corporation to provide QuickVue At-Home OTC COVID-19 Test 's free-of-charge to multiple Chicago Blackhawks Foundation community partners to help support local youth and their program staff to continue to learn and play with greater peace of mind .

Quidel Announces Sponsorship and Community Partnership With the Chicago Blackhawks

In the first year of the partnership agreement , the Blackhawks will work with Quidel Corporation to provide QuickVue At-Home OTC COVID-19 Test 's free-of-charge to multiple Chicago Blackhawks Foundation community partners to help support local youth and their program staff to continue to learn and play with greater peace of mind .

Quidel Corporation - Quidel Announces Sponsorship and Community Partnership With the Chicago Blackhawks

In the first year of the partnership agreement , the Blackhawks will work with Quidel Corporation to provide QuickVue At-Home OTC COVID-19 Test 's free-of-charge to multiple Chicago Blackhawks community partners to help support local youth and their program staff to continue to learn and play with greater peace of mind .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Quidel Service Providers

2 Service Providers

Quidel has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired Unit

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acquired Unit

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

Quidel Team

2 Team Members

Quidel has 2 team members, including current Chief Financial Officer, Steven Burke.

Name

Work History

Title

Status

Steven Burke

Chief Financial Officer

Current

John Radak

Chief Financial Officer

Former

Name

Steven Burke

John Radak

Work History

Title

Chief Financial Officer

Chief Financial Officer

Status

Current

Former

You May Also Like

BD Logo
BD

BD is a medical technology company that manufactures and sells a broad range of supplies, devices, and systems for use by healthcare professionals, medical research institutions, industry, and the general public.

i
iAssay

iAssay is a provider of point of care diagnostics solutions. The company provides an open platform for wirelessly connected point of care (POC) diagnostics. The device aggregates test, patient, and wearables data and pushes all data into the cloud. The aim is to eliminate test result delays, delayed diagnosis, sample handling and transportation costs. It also aim to improve patient outcomes and save the healthcare system money.

S
SpinChip Diagnostics

SpinChip Diagnostics develops in vitro point of care systems that use lab-on-a-chip technology for the diagnosis of cardiovascular, endocrine, anemic, diabetic, infectious ad inflammatory diseases.

S
Siemens Healthineers

Siemens Healthineers is the separately managed healthcare business of Siemens, enabling healthcare providers worldwide to meet their current challenges and to excel in their respective environments. Siemens Healthineers is constantly expanding its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services.

Abbott Logo
Abbott

Abbott (NYSE: ABT) is a global healthcare company with a portfolio of science-based offerings in diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.